The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH 2017 | The drugs being used to treat newly diagnosed AML patients
In this insightful interview, Mark Levis, MD, PhD, from The Johns Hopkins Hospital, Baltimore, MD, talks about the four primary drugs that are being used to treat newly diagnosed acute myeloid leukemia (AML) patients. These include midostaurin, gemtuzumab ozogamicin, idarubicin and enasidenib; all of which are targeted at different subgroups of AML. This interview was recorded at the International Conference on Acute Myeloid Leukemia 2017 in Estoril, Portugal by the European School of Hematology (ESH).
